Trial Profile

Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remternetug (Primary) ; Remternetug (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms TRAILRUNNER-ALZ 1
Sponsors Eli Lilly and Company

Most Recent Events

09 Dec 2024 Planned End Date changed from 31 Mar 2026 to 1 Mar 2026.
16 Aug 2024 Status changed from recruiting to active, no longer recruiting.
16 Aug 2024 Planned End Date changed from 1 Oct 2026 to 31 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com